| Cyclic peptides as drugs for intracellular targets: the next frontier in peptide therapeutic development LK Buckton, MN Rahimi, SR McAlpine Chemistry–A European Journal 27 (5), 1487-1513, 2021 | 124 | 2021 |
| Synthesis and Structure–Activity Relationships of Inhibitors That Target the C-Terminal MEEVD on Heat Shock Protein 90 MN Rahimi, LK Buckton, SS Zaiter, J Kho, V Chan, A Guo, J Konesan, ... ACS Medicinal Chemistry Letters 9 (2), 73-77, 2017 | 28 | 2017 |
| Protein–protein inhibitor designed de novo to target the MEEVD region on the C-terminus of Hsp90 and block co-chaperone activity MN Rahimi, SR McAlpine Chemical Communications 55 (6), 846-849, 2019 | 22 | 2019 |
| Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts CE Toscan, M Rahimi, M Bhadbhade, R Pickford, SR McAlpine, RB Lock Organic & Biomolecular Chemistry 13 (22), 6299-6312, 2015 | 16 | 2015 |
| RITA mimics: synthesis and mechanistic evaluation of asymmetric linked trithiazoles AL Pietkiewicz, Y Zhang, MN Rahimi, M Stramandinoli, M Teusner, ... ACS Medicinal Chemistry Letters 8 (4), 401-406, 2017 | 7 | 2017 |
| Polymer mediated transport of the Hsp90 inhibitor LB76, a polar cyclic peptide, produces an Hsp90 cellular phenotype MN Rahimi, HG Foster, SN Farazi, R Chapman, SR McAlpine Chemical Communications 55 (31), 4515-4518, 2019 | 5 | 2019 |
| Delivering bioactive cyclic peptides that target Hsp90 as prodrugs Y Huo, LK Buckton, JL Bennett, EC Smith, FL Byrne, KL Hoehn, ... Journal of Enzyme Inhibition and Medicinal Chemistry 34 (1), 728-739, 2019 | 4 | 2019 |
| Development of Highly Potent Clinical Candidates for Theranostic Applications against Cholecystokinin-2 Receptor Positive Cancers A Corlett, JA Pinson, MN Rahimi, JV Zuylekom, C Cullinane, B Blyth, ... Journal of Medicinal Chemistry 66 (15), 10289-10303, 2023 | 2 | 2023 |
| Precision peptide theranostics: developing N-to C-terminus optimized theranostics targeting cholecystokinin-2 receptor MN Rahimi, A Corlett, J Van Zuylekom, MA Sani, B Blyth, P Thompson, ... Theranostics 14 (5), 1815, 2024 | | 2024 |
| First-In-Class Diagnostics Targeting Neuropeptide Y1 Receptor (Y1R): Enabling Molecular Imaging of Metastatic Breast Cancer MN Rahimi, J Van Zuylekom, N Mason, B Blyth, P Thompson, M Haskali NUCLEAR MEDICINE AND BIOLOGY 126, S293-S294, 2023 | | 2023 |
| The Next Generation of Tumour Homing Peptides: Foldamers at the Forefront of Precise Cancer Theranostics MN Rahimi, A Corlett, J Van Zuylekom, P Roselt, B Blyth, P Thompson, ... Nuclear Medicine and Biology 126, 108794, 2023 | | 2023 |
| First-In-Class Diagnostics Targeting Neuropeptide Y1 Receptor (Y1R): Enabling Molecular Imaging of Metastatic Breast Cancer MN Rahimi, J Van Zuylekom, N Mason, B Blyth, P Thompson, M Haskali Nuclear Medicine and Biology 126, 108792, 2023 | | 2023 |
| Structure-activity relationship study of peptide Gastramide-01 (GA-01), a potent binder of cholecystokinin-2 (CCK-2) receptor and theranostic candidate M Rahimi, A Corlett, J Van Zuylekom, B Blyth, P Thompson, M Haskali Nuclear Medicine and Biology 96, S107, 2021 | | 2021 |
| Investigating cyclic peptide inhibitors of heat shock protein 90 (Hsp90): from design and synthesis to cellular drug delivery MN Rahimi UNSW Sydney, 2020 | | 2020 |
